Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;56(3):1835-1842.
doi: 10.1007/s42770-025-01711-z. Epub 2025 Jul 15.

In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix

Fernando Almeida-Silva  1 , Fernanda Praça Nogueira Marques  2 , Pedro Henrique Tenório-Alvarenga  2 , Vanice Rodrigues Poester  3 , Melissa Orzechowski Xavier  3 , Rosely Maria Zancopé-Oliveira  2 , Rodrigo Almeida-Paes  2
Affiliations

In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix

Fernando Almeida-Silva et al. Braz J Microbiol. 2025 Sep.

Abstract

Sporotrichosis is an endemic mycosis that pose significant public health challenges, particularly in Brazil, where zoonotic transmission has increased the number of cases in several regions of the country. The disease is caused by Sporothrix genus, with S. brasiliensis, S. schenckii, and S. globosa as the major agents. The currently available therapies may face limitations such as varying cure rates, long and expensive treatment, and adverse effects. Fosmanogepix, a prodrug converted into manogepix within the host, has demonstrated broad-spectrum antifungal activity, including other thermodimorphic fungal species. Thus, this study aimed to evaluate the in vitro antifungal efficacy of manogepix against three clinically relevant Sporothrix species. Minimal inhibitory and fungicidal concentrations were determined against 24 Sporothrix spp. isolates, as well as potential synergism with antifungal drugs, induction of resistance and growth kinetics of the fungus in the presence of the new antifungal drug. Manogepix exhibited fungicidal activity against the three Sporothrix species tested, with minimum inhibitory concentrations (MIC) ranging from 0.06 to 1 µg/ml. Furthermore, manogepix demonstrated a lower geometric mean of MIC values compared to the antifungal drugs and indifferent interactions with itraconazole, terbinafine and amphotericin B. Prolonged exposure to subinhibitory manogepix concentrations did not induce resistance in the tested strains. These findings indicate manogepix as a promising candidate for the treatment of sporotrichosis, offering a potential alternative in cases of resistance or treatment failure with current antifungals. Further studies are needed to confirm this activity in clinical settings, particularly in diverse geographic regions and against a broader range of Sporothrix strains.

Keywords: Antifungal activity; Fosmanogepix; Sporotrichosis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

    1. Curtis KL, Gold JAW, Ritter JM, Rosen T, Santos DWCL, Smith DJ, Lipner SR (2024) Dermatologic fungal neglected tropical diseases-Part I. Epidemiology and clinical features. J Am Acad Dermatol S0190–9622(24)00849–1. 10.1016/j.jaad.2024.03.056 - PMC - PubMed
    1. Alzuguir CLC, Pereira SA, Magalhães MAFM, Almeida-Paes R, Freitas DFS, Oliveira LFA, Pimentel MIF (2020) Geo-epidemiology and socioeconomic aspects of human sporotrichosis in the municipality of Duque de Caxias, Rio de Janeiro, Brazil, between 2007 and 2016. Trans R Soc Trop Med Hyg 114(2):99–106. 10.1093/trstmh/trz081 - PubMed
    1. Gremião IDF, Oliveira MME, Monteiro de Miranda LH, Saraiva Freitas DF, Pereira SA (2020) Geographic expansion of Sporotrichosis, Brazil. Emerg Infect Dis 26(3):621–624. 10.3201/eid2603.190803 - PMC - PubMed
    1. Orofino-Costa R, Freitas DFS, Bernardes-Engemann AR, Rodrigues AM, Talhari C, Ferraz CE, Veasey JV, Quintella L, Sousa MSLA, Vettorato R, Almeida-Paes R, de Macedo PM (2022) Human sporotrichosis: recommendations from the Brazilian Society of Dermatology for the clinical, diagnostic and therapeutic management. An Bras Dermatol. 97(6):757–777. 10.1016/j.abd.2022.07.001 - PMC - PubMed
    1. Bonifaz A, Tirado-Sánchez A (2017) Cutaneous disseminated and extracutaneous Sporotrichosis: Current status of a complex disease. J Fungi (Basel) 3(1):6. 10.3390/jof3010006 - PMC - PubMed

LinkOut - more resources